Becton, Dickinson and Company Earnings Recaps
BD's shares rose 3.6% post-earnings, driven by revenue growth above expectations and an upward revision to adjusted EPS guidance, signaling market approval of the company’s focused portfolio and operational execution.
Key takeaways
- Revenue reached $5 billion, up 4.4% year-over-year on an FX-neutral basis, with over 90% of the portfolio delivering high single-digit growth.
- Adjusted operating margin expanded to 24.9%, reflecting improved mix and operational efficiency under the BD Excellence program.
- Adjusted EPS came in at $3.23, prompting a raised midpoint for full-year EPS guidance and updated revenue growth target toward the high end of low single digits.
- Broad-based growth was supported by double-digit expansion in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration platforms.
- Commercial investments in key segments like Advanced Patient Monitoring and PureWick contributed to accelerating growth and share gains, particularly in the U.S. market.
BD's shares rose 3.2% post-earnings, reflecting investor approval of solid revenue growth and margin expansion driven by strong execution across key growth platforms and an upgraded full-year EPS outlook.
Key takeaways
- Revenue grew 2.6% to $4.7 billion, led by double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration.
- Adjusted operating margin improved to 24.2%, supporting adjusted EPS of $2.90, which exceeded management expectations.
- More than 90% of the portfolio delivered mid-single-digit growth, indicating broad-based strength despite targeted pressure in Alaris, vaccines, and China.
- Management raised full-year adjusted EPS guidance, signaling confidence in the New BD strategy’s ability to drive sustainable growth and improve capital allocation.
- Commercial execution gains included notable share increases in Alaris and accelerated customer adoption in Connected Care and BioPharma Systems.
Becton, Dickinson and Company reported stronger-than-expected Q1 results for fiscal 2026, driven by disciplined execution and robust growth across key areas, despite challenges in certain segments.
Key takeaways
- Revenues reached $5.3 billion, with new segments growing by 2.5% supported by double-digit growth in biologic drug delivery and advanced tissue regeneration.
- Adjusted gross margin improved to 53.4%, and adjusted EPS was $2.91, both exceeding expectations.
- The company is set to close a significant Reverse Morris Trust transaction with Waters, unlocking $4 billion in cash, with plans to allocate $2 billion to share repurchases and $2 billion for debt reduction.
- Enhanced capital allocation strategy emphasizes share buybacks, consistent dividends, and focused M&A to drive return on invested capital.
BD reported a solid Q4 with revenues of $5.9 billion, reflecting a 7% year-over-year increase, while the full year saw record revenues of $21.8 billion, supported by strong organic growth across key segments.
Key takeaways
- Q4 adjusted diluted EPS increased to $3.96, contributing to a full-year record of $14.40, driven by efficient operations and revenue growth.
- New BD's organic growth accelerated to 4.9%, demonstrating resilience despite pressure from vaccine demand fluctuations and research funding constraints.
- The company returned $2.2 billion to shareholders, including a significant $1 billion share buyback, while announcing its 54th consecutive dividend increase.
- Initiatives to optimize performance include restructuring for commercial excellence, expanding the sales force, and investing $50 million into R&D to drive future innovation and growth.
- BD's robust portfolio and strategic investments position it for continued mid-single-digit growth amidst ongoing market dynamics.